The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway–driven advanced solid tumors.
 
Tiago Reis Marques
Employment - Pasithea Therapeutics
Leadership - Pasithea Therapeutics
Stock and Other Ownership Interests - Pasithea Therapeutics
Travel, Accommodations, Expenses - Pasithea Therapeutics
 
Mathew Lazarus
Employment - Pasithea Therapeutics
Stock and Other Ownership Interests - Pasithea Therapeutics
 
Joy Cannon
Employment - Pasithea Therapeutics
Travel, Accommodations, Expenses - Pasithea Therapeutics
 
Ildefonso Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology
Consulting or Advisory Role - Cardinal Health; Syneos Health; Telix Pharmaceuticals; Werewolf Therapeutics